Study of Durvalumab Given with Chemoradiation Therapy in Patients with Unresectable Non-small Cell Lung Cancer

Exclusion Criteria

• :
• - Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs.
• - Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.
• - History of allogeneic organ transplantation
• - Active or prior documented autoimmune or inflammatory disorders
• - Uncontrolled intercurrent illness
• - History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency
• - Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
• - Mixed small cell and NSCLC histology
• - Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling
• - Known allergy or hypersensitivity to any of the IPs or any of the IP excipients.
• - Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.